Psychedelics enter mainstream cancer care discussions as clinicians examine distress relief, end-of-life anxiety, and the evidence needed for safe adoption

Psychedelics are moving into cancer care conversations as clinicians and researchers consider whether they can ease depression, existential distress, and end-of-life anxiety in people facing serious illness. Interest centers on how carefully supervised treatment might complement supportive oncology and palliative care rather than function as a stand-alone cure. Psilocybin, MDMA, and ketamine are the substances most likely to anchor that discussion because they already have clinical research pathways, recognizable safety questions, and growing public visibility. Key issues include screening for psychiatric risk, therapist support, regulatory barriers, durability of benefit, and whether effects seen in small or selective studies can translate into routine cancer settings. Cancer care institutions, patients, and policymakers all face a practical question: what level of evidence, training, and safeguards would justify broader use. The stakes are high because psychological suffering in oncology is common, existing treatments often fall short, and premature adoption could outpace the data needed for safe implementation.